Diagnosis and Treatment of Recurrent Cervical Cancer.
10.5124/jkma.2007.50.9.796
- Author:
Sang Yoon PARK
1
Author Information
1. Department of Obstetrics and Gynecology, National Cancer Center, Korea. parksang@ncc.re.kr
- Publication Type:Original Article
- Keywords:
Recurrent cervical cancer;
Pelvic exenteration;
Radiotherapy;
Chemotherapy
- MeSH:
Diagnosis*;
Disease-Free Survival;
Drug Therapy;
Female;
Fistula;
Humans;
Hysterectomy;
Neoplasm Metastasis;
Pelvic Exenteration;
Radiotherapy;
Recurrence;
Uterine Cervical Neoplasms*
- From:Journal of the Korean Medical Association
2007;50(9):796-806
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Despite recent advances in the early detection method and treatment modalities (surgery and/or radiation and/or chemotherapy), cervical cancer is still an important malignant disease in women. Almost half a million new cases occur every year in the world. The management of recurrent cervical cancers depends on primary treatment, the extent of disease, and performance status. Patients who received primary surgical treatment without radiotherapy (RT) may undergo curative RT. However, most recurrences occur in patients with advanced-stage disease already treated by primary RT. For patients who failed primary RT or surgery plus adjuvant RT and had central relapse without pelvic sidewall recurrence, pelvic exenteration may be necessary. For patients who had pelvic sidewall recurrences, pelvic exenteration is usually not an option with curative intent. In such situation, combined operative and radiotherapeutic treatment (CORT), and laterally extended endopelvic resection (LEER), intraoperative radiotherapy (IORT) have been executed with some success. Simple or radical hysterectomy can be considered for patients who had small uterine and/or vaginal recurrences, but the high frequency of associated morbidities such as urinary and bowel tract injury or fistula is the problem. Patients with multiple or distant metastases are destined to receive cisplatin-based palliative chemotherapy. Recently there was a GOG 179 study that had firstly shown a statistically significant improvement on the overall response rate, median progression-free survival, and median survival. Until now, however, the role of chemotherapy has been very limited.
